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Abstract
Background: The gametocyte sex ratio of Plasmodium falciparum, defined as the proportion of
gametocytes that are male, may influence transmission but little is known of the effects of
mefloquine or artesunate-mefloquine on gametocyte sex ratio and on the sex ratio of first
appearing gametocytes.
Methods: 350 children with uncomplicated P. falciparum malaria were enrolled in prospective
treatment trial of mefloquine or artesunate-mefloquine between 2007 and 2008. Gametocytaemia
was quantified, and gametocytes were sexed by morphological appearance, before and following
treatment. The area under curve of gametocyte density versus time (AUCgm) was calculated by
linear trapezoidal method.
Results: 91% and 96% of all gametocytes appeared by day 7 and day 14, respectively following
treatment. The overall rate of gametocytaemia with both treatments was 31%, and was significantly
higher in mefloquine than in artesunate-mefloquine treated children if no gametocyte was present
a day after treatment began (25.3% v 12.8%, P = 0.01). Gametocyte clearance was significantly faster
with artesunate-mefloquine (1.8 ± 0.22 [sem] v 5.6 ± 0.95 d; P = 0.001). AUCgm was significantly
lower in the artesunate mefloquine group (P = 0.008). The pre-treatment sex ratio was male-
biased, but post-treatment sex ratio or the sex ratio of first appearing gametocytes, was
significantly lower and female-biased two or three days after beginning of treatment in children
given artesunate-mefloquine.
Conclusion: Addition of artesunate to mefloquine significantly modified the emergence, clearance,
and densities of gametocytes and has short-lived, but significant, sex ratio modifying effects in
children from this endemic area.
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Background
Gametocytes are crucial for malaria transmission from the
human host to the mosquito vector. Although the exact
mechanisms of gametocytogenesis are unclear and many
individual mosquitoes that ingest gametocytes do not
support their development to sporozoite stage [1], anti-
malarials, as well as other factors such as host genetic or
immune status may significantly influence the process of
gametocytogenesis and the development of gametocytes
in individual mosquitoes [2,3].
The persistence, in peripheral blood, of Plasmodiun falci-
parum gametocytes has been estimated to vary from 3-21
days [4-6]. However, the emergence and clearance game-
tocytes have been less frequently evaluated in therapeutic
efficacy studies in general and have not been investigated
in African children treated with mefloquine or atresunate-
mefloquine in particular.
In natural populations, the Plasmodium spp gametocyte sex
ratio is female biased, but this ratio can vary significantly
during the course of individual infections [7-9]. Although
anti-malarials may significantly influence the temporal
changes in gametocyte sex ratio [10,11], the exact contri-
bution of chemotherapy to these changes is difficult to
quantify because many confounding variables such as
gametocyte density, host anaemia, host cell preference
and, kin discrimination in malaria parasites influence sex
allocation strategies in the parasite [7,9,12,13].
Artesunate-mefloquine combination is increasingly used
on the African continent for the treatment of acute falci-
parum malaria. However, the individual components of
artesunate-mefloquine are readily available and used in
Africa; it is desirable to evaluate the effects of both meflo-
quine and artesunate mefloquine on gametocyte carriage
and sex ratio. In addition, it is important to assess how
these drugs influence the first appearance of gametocytes
in African children following treatment of uncomplicated
infections. The information from these evaluations may
assist in planning control measures.
The aims of the present study are to evaluate the emer-
gence and clearance of gametocytes; the rate of gametocy-
taemia; the temporal changes in sex ratio; and the sex ratio
of first appearing gametocytes in children treated for acute
falciparum malaria with mefloquine or artesunate plus
mefloquine in an endemic area of southwestern Nigeria.
Methods
Patients
The study was conducted between July 2007 and August
2008 in children aged ten years or below with acute
uncomplicated  P. falciparum malaria in Ibadan, south-
western Nigeria, an endemic area of malaria [14]. Fully-
informed consent was obtained from the parents/guardi-
ans of each child. Inclusion criteria were: fever or history
of fever in the 24-48 h preceding presentation, pure P. fal-
ciparum  parasitaemia ≥ 2000 asexual forms/μL, a body
(axillary) temperature > 37.4°C or history of fever in the
24-48 h preceding presentation, absence of other con-
comitant illness, no history of anti-malarial use in the two
weeks preceding presentation, and negative urine tests for
anti-malarial drugs (Dill-Glazko and lignin). Patients
with severe malaria [15], severe malnutrition, serious
underlying diseases (renal, cardiac, or hepatic), and
known allergy to study drugs were excluded from the
study. The study protocol was approved by the local ethics
committee.
Drug management
After clinical assessment, blood was obtained for haemat-
ocrit determination and for quantification of asexual and
sexual parasitaemia. Patients were randomized to (i) a
single dose regimen of mefloquine 25 mg/kg on presenta-
tion (day 0), or (ii) artesunate at 4 mg/kg daily for three
days (day 0-2) plus mefloquine given as in (i) above. All
drugs were given orally and all patients waited for at least
three hours after to ensure the drug was not vomited. If it
was, the patient was excluded form the study.
Oral paracetamol (acetaminophen) at 10-15 mg/kg 6-8
hourly was given for 12-24 h if body temperature was >
38°C. Patients were seen daily, at approximately the same
time of the day for the first eight days (days 0-7) and then
on days 14, 21, 28, 35 and 42 after treatment had begun.
At each visit, patients were assessed clinically and thick
and thin blood smears were obtained for quantification of
parasitaemia. The fever clearance time was defined as the
time taken for body temperature to fall to below 37.5°C
and remain below this value for > 48 h.
Laboratory investigations
Thick and thin blood films prepared from a finger prick
were stained with 10% Giemsa for 30 minutes and were
examined by light microscopy under an oil-immersion
objective, at 1000× magnification by two independent
assessors who did not know the drug treatment of the
patient. A senior member of the study team reviewed the
slides, if there was any disagreement between the micro-
scopists. In addition, the slides of every third child
enrolled in the study were reviewed by this senior mem-
ber.
Asexual parasite and gametocyte counts were measured
daily for the first eight days (days 0-7) and thereafter on
days 14, 21 and 28. Quantification of asexual and sexual
parasites in Giemsa-stained thick blood films was done
against 500 leukocytes in the case of asexual parasitaemia,
and against 1,000 leukocytes in the case of gametocytes.Malaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
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From this figure, the parasite density was calculated
assuming a leukocyte count of 6,000/μl of blood. Asexual
parasite clearance time was the time interval from the start
of anti-malarial treatment until the asexual parasite count
fell below detectable levels in a peripheral blood smear.
Gametocyte clearance time was the interval between the
first and last positive smears for gametocytes. Capillary
blood, collected before and during follow-up, was used to
measure packed cell volume (PCV). PCVs were measured
using a microhaematocrit tube and microcentrifuge
(Hawksley, Lancing, UK). Routine haematocrit was done
on days 0, 3, 7, 14, 21 and 28.
Determination of gametocyte sex and gametocyte sex 
ratio
Gametocyte sex determination was based on the follow-
ing criteria [16,17]: males (microgametocytes) are smaller
than females (macrogametocytes), the nucleus is larger in
males than females, the ends of the cells are rounder in
males and angular in females, with Giemsa the cytoplasm
stains purple in males and deep blue in females, and the
granules of malaria pigment are centrally located females
and more widely scattered in males. Gametocytes were
sexed if at least three of the five criteria stated above were
present and if the gametocyte density was ≥ 15/μl blood.
The sex ratio was defined as the proportion of gametocytes
that were male [18].
For each patient, gametocyte densities were plotted
against time. The areas under the curve of gametocytaemia
versus time (AUCgm) were determined by a non-compart-
mental method using the computer programme Turbo Ken
(Clinical Pharmacology Group, University of Southamp-
ton, UK, through the courtesy of Prof. A.G. Renwick) as
previously described [11]. Briefly, AUCgm was obtained,
using the linear trapezoidal rule from time zero (0 h, day
0) to the time of gametocyte clearance, or if there was no
clearance, until 1008 h (day 42). The final gametocyte
density at the time of clearance was assumed to be 0.001
sexual forms/μl blood (a level assumed to be below
microscopic detection).
Data analysis
Data were analysed using Epi-Info version 6 [19], and the
statistical programme SPSS for Windows version 10.01
[20]. Variables considered in the analysis were related to
the densities of P. falciparum gametocytes and tropho-
zoites. Proportions were compared by calculating χ2 with
Yates' correction or by Fisher exact or by Mantel Haenszel
tests. Normally distributed, continuous data (e.g. fever,
asexual parasite and gametocyte clearance times) were
compared by Student's t-tests and analysis of variance
(ANOVA). Data not conforming to a normal distribution
(e.g. asexual and sexual parasite densities, gametocyte sex
ratio, and area under curve of gametocytaemia versus
time) were compared by the Mann-Whitney U-tests and
the Kruskal-Wallis tests (or by Wilcoxon ranked sum test).
Kaplan-Meier plots are also presented to compare gameto-
cyte carriage rates following treatment. Differences in sur-
vival time were assessed by inspection of Kaplan-Meier
curves and log-rank tests. All tests of significance were
two-tailed. P-values of < 0.05 were taken to indicate signif-
icant differences. Data were (double)-entered serially
using the patients codes and were only analysed at the end
of the study.
Results
Patients
Three hundred and fifty patients were recruited: 174 in
atresunate-mefloquine group and 176 in mefloquine
group. All children completed at least 14-21 days of fol-
low up. The baseline characteristics of children with
gametocytaemia are summarized in Table 1. These charac-
teristics were similar in the two treatment groups. How-
ever, parasite but not fever clearance was significantly
faster in children treated with artesunate-mefloquine.
First detection of gametocytaemia
Table 2 summarizes the times of detection of gametocytes.
Overall, 72%, 91% and 96% of all gametocytes were
detectable by days 3, 7, and 14, respectively. The rates of
detection were similar in the two treatment groups.
Gametocytaemia
Gametocytes were detected in peripheral blood in 108
children (31%) from the two treatment groups. Thus the
overall proportions of children with gametocytaemia was
31%. The proportion was 12.8% and 25.3% for artesu-
nate-mefloquine and mefloquine alone, respectively if no
gametocytes were present by day 1 after enrolment (Table
2). The difference between these proportions was signifi-
cant (P = 0.01).
The overall detection rate at enrolment was 12% and was
not significantly different between the two treatment
groups: 20 of 171 (11.4%) versus 22 of 171 (12.6%), in
the mefloquine and artesunate-mefloquine groups,
respectively, P = 0.71. After treatment, the emergence of
gametocytes was significantly less frequent in the artesu-
nate-mefloquine group than in the mefloquine alone
group: 22 of 171 (12.6%) versus 44 of 171 (25%), respec-
tively, P = 0.004. Post-treatment, gametocyte carriage was
significantly higher than pre-treatment in the mefloquine
alone group (20 of 171 versus 44 of 171, P = 0.0009) but
not in the artesunate-mefloquine group (22 of 171 versus
22 of 171, P = 1.00).
Duration of gametocyte carriage
The probability of mosquito infectivity is related to game-
tocyte density and the duration of carriage by the host.Malaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
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Figure 1, a Kaplan-Meier plot of the cumulative probabil-
ity of being gametocyte free during the first week of fol-
low-up was significantly higher in the artesunate-
mefloquine treated than in mefloquine alone treated chil-
dren (log rank statistic = 9.85, P = 0.002).
AUCgm was determined in patients who carried gameto-
cytes at least on three occasions within 14 days. The mean
AUCgm were (501.7 ± 115.6 (SEM), 95% confidence inter-
val (95% CI) 261.4-742.0 sexual forms/μl.d in meflo-
quine-treated children and (186.7 ± 71.2 (SEM), 95% CI
22.4-351.0 sexual forms/μl.d in artesunate-mefloquine
treated children (Figures 2 and 3). The difference between
these values was significant (P = 0.008). The mean AUCgm
was 2.7-fold higher in mefloquine than in artesunate-
mefloquine treated children.
Clearance of gametocytes
Only seven children, all treated with mefloquine alone,
had gametocytes on or after day 14. Overall, gametocyte
clearance was significantly faster in the artesunate-meflo-
quine group than in the mefloquine alone group (1.8 ±
0.22 [sem], range 1-8 versus 5.6 ± 0.95, range 1-35 d; P =
0.001) (Table 3). Gametocytes were cleared within four
days in 95% and 63% of children treated with artesunate-
mefloquine and mefloquine alone, respectively. The dif-
ference between these proportions was significant (χ2 =
13.74, P = 0.0002).
Table 1: Demographic data and immediate therapeutic response of children with P falciparum gametocytaemia treated with 
mefloquine or artesunate-mefloquine
Values* for the following treatment groups P. value
Parameter Artesunate-Mefloquine Mefloquine All
No. of patients 44 64 108 -
Male/Female 22/22 32/32 54/54 -
Age (year) 6.1 ± 3.1 6.9 ± 2.8 6.5 ± 2.9 0.18
1-13 0.8-13 0.8-13
No. < 5 years 14 12 26
Weight (kg) 18.2 ± 7.1 19.4 ± 5.6 18.9 ± 6.3 0.31
8-46 7-33 7-46
Height (cm) 109.2 ± 19.4 115.2 ± 16.1 112.7 ± 17.7 0.09
65-141 74-147 65-147
Duration of illness (d) 2.5 ± 0.9 3.1 ± 1.4 2.9 ± 1.3 0.01
1-5 1-7 1-7
Body temperature (°C) 38.3 ± 1.2 38.2 ± 1.2 38.2 ± 1.2 0.6
36.2-40.5 35.2-40.5 35.2-40.8
Parasite count (/μL)
Geometric mean 29280 27760 28590
Range 2200-884571 2400-520000 2200-884571
Gametocyte density (/μL)
Geometric mean 18 28 23 0.24
Range 6-216 6-468 6-468
Fever clearance time (d)
1.3 ± 0.6 (n = 30) 1.3 ± 0.8 (n = 40) 1.3 ± 0.7 0.86
1-3 1-5 1-5
Parasite clearance time (d)
1.4 ± 0.5 1.9 ± 0.8 1.7 ± 0.8 0.003
1-3 1-4 1-4
Data are shown as mean ± SD or median (range),Malaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
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Temporal changes in sex ratio following treatment
In 64 children who had gametocytaemia at presentation
or during follow-up in the mefloquine group, a total of
202, 222, 263, 163, 165, 116, 123, 176, 65, 14, 62, 95 and
26 were counted but 184, 205, 230, 134, 145, 103, 121,
165, 65, 14, 62, 95, and 26 could be sexed on days
0,1,2,3,4,5,6,7,14, 21, 28, 35 and 42, respectively. In 44
children who had gametocytaemia at presentation or dur-
ing follow-up, in the artesunate plus mefloquine group, a
total of 126, 122, 37, 72, 3, 3, 5, 13, 5, 3 and 2 were
counted but 120, 110, 23, 65, 3, 3, 5, 11, 6, 3, and 2 could
be sexed on days 0, 1, 2,3, 4, 5, 6, 7, 14, 21 and 35, respec-
tively. Thus, very few gametocytes were present in those
treated with artesunate plus mefloquine when compared
with those treated with mefloquine alone.
The variations in sex ratio following treatment are shown
in Figure 4. Sex ratio at enrolment in both treatment
groups was male-biased and was not significantly differ-
ent in the mefloquine and mefloquine-artesunate treated
children (0.76 ± 0.07 (SEM) v 0.73 ± 0.07, P = 0.76).
However, sex ratio values 2 d after treatment began were
significantly lower and more female-biased in the artesu-
nate-mefloquine group compared with the mefloquine
alone group (0.35 ± 0.15 (SEM) v 0.76 ± 0.07, P = 0.02).
In addition, this value for artesunate-mefloquine was sig-
nificantly lower than pre-treatment mean sex ratio (P =
0.04). In mefloquine treated children, the corresponding
values were similar (P = 0.93).
Sex ratio of first-appearing gametocytes
Overall, the sex ratio of first appearing gametocytes was
male-biased in mefloquine treated children. In artesu-
nate-mefloquine treated children, sex ratio of first appear-
ing gametocytes three days after treatment began became
female-biased and was significantly lower (P = 0.04) in
the artesunate-mefloquine than in the mefloquine alone
group (Figure 5).
Discussion
The overall gametocyte carriage rate of 12% at enrolment
is consistent with previous findings in this and other
endemic areas [6,11,21-23] but may be an underestimate
since sub-microscopic gametocytaemia detectable by
polymerase chain reaction (PCR) is not uncommon in
children from this and other endemic areas [24-26].
Indeed submicroscopic gametocytaemia is present in 15%
of children from this endemic area following treatment
with artemether-lumefantrine [26].
Only 40% of gametocytaemic patients were identified on
presentation. This proportion is significantly lower than
72% recorded in an area of lesser intensity of transmission
in Thailand [27]. The reasons for this region- or transmis-
sion intensity-related difference are not immediately
apparent from the results of the present study. That 35%
of all gametocytes emerged after completion of treatment
(Table 2) may have implications for the present treatment
policy in Africa and suggests that artemisinins and artem-
isinin-based combination therapy are not rapidly gameto-
cytocidal during the early acute phase of the infections
[26].
The risk of gametocyte carriage following treatment with
anti-malarials varies considerably; the risk is often higher
with monotherapy than with artemisinin combination
therapy [6,11,22,28], and in the study area, is highest with
antifolate monotherapy [11]. In the present study, the
proportion of patients developing a gametocytaemia if
none was present by one day after treatment began was
twice as high with mefloquine compared with artesunate-
mefloquine. This time-related increase in proportion of
Table 2: First appearance of gametocytes in children with P. falciparum malaria treated with treated with mefloquine or artesunate-
mefloquine
No. with gametocytes
Days after enrolment Artesunate-Mefloquine Mefloquine All Cumulative %
02 2 2 0 4 2 3 8 . 9
13 6 9 4 7 . 2
26 1 3 1 9 6 4 . 8
33 5 8 7 2 . 2
41 3 4 7 5 . 9
51 2 3 7 8 . 7
61 3 4 8 2 . 4
73 6 9 9 0 . 7
14 3 3 6 96.3
21 - 2 2 98.1
28 - 1 1 99.1
35 1 - 1 100
42 - - - 100
Total 44 64 108 100Malaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
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patients with gametocytaemia after administration of two
daily doses of an artemisinin-based combination therapy
may allow an objective assessment of the effects of anti-
malarial drugs on gametocyte carriage. The time-related
increase in proportion is dependent primarily on the
rapidity of clearance of asexual parasitaemia with a conse-
quently reduced chance of development of gametocytae-
mia and, secondarily on the rate of clearance of sexual
parasitaemia. Thus, as shown in Thailand [28], the signif-
icantly rapid clearance of asexual parasitaemia by artesu-
nate-mefloquine compared with mefloquine alone
contributed to this relatively reduced proportion of
patients with gametocytaemia in the present study. How-
ever, the relatively high proportion of children with game-
tocytaemia (12.8%) after artesunate-mefloquine, again
suggests that despite relatively rapid asexual parasiticidal
action, artemisinins are not gametocytocidal for mature
gametocytes. In addition, this proportion is considerably
greater than 1.9% recorded in an area of lesser intensity of
transmission in Thailand [27], suggesting that the chance
of being gametocytaemic increases as transmission inten-
sity increases.
Survival curve of cumulative probability of remaining gametocyte-free 7 days following treatment with mefloquine (solid line) or  artesunate plus mefloquine (solid broken line) for gametocytaemic children (log-rank statistic = 9.85, P = 0.002) Figure 1
Survival curve of cumulative probability of remaining gametocyte-free 7 days following treatment with meflo-
quine (solid line) or artesunate plus mefloquine (solid broken line) for gametocytaemic children (log-rank sta-
tistic = 9.85, P = 0.002).
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Area under curve of gametocyte density versus time in children treated with mefloquine (black closed circle on dashed line) or  artesunate mefloquine (open circle on solid line) Figure 2
Area under curve of gametocyte density versus time in children treated with mefloquine (black closed circle on 
dashed line) or artesunate mefloquine (open circle on solid line).
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Distribution of AUCgm values in children treated with mefloquine (MQ) or aresunate mefloquine (AMQ) Figure 3
Distribution of AUCgm values in children treated with mefloquine (MQ) or aresunate mefloquine (AMQ). Hori-
zontal bars indicate mean values.
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The significantly higher post-treatment gametocyte car-
riage in children treated with mefloquine alone suggest
that the slow clearance of asexual parasitaemia (inde-
pendent of recrudescence) may be primarily responsible
for the progression of committed asexual parasites to
develop to gametocytes. Recrudescence in both meflo-
quine and artesunate-mefloquine is associated with game-
tocytaemia [28,29]. The similar pre- and post-treatment
gametocytaemia in those treated with artesunate-meflo-
quine suggests moderate effects of artesunate on gameto-
cyte carriage. This observation, in the context of
artemisinin based comnination therapy (ACT) supports a
recent finding from East and West Africa [24,26].
The study evaluated the effects of treatment with meflo-
quine or artesunate-mefloquine on gametocyte clearance
and sex ratio in children who were gametocytaemic
before, during or after treatment commenced. To our
knowledge, this is the first study of the effects of these
drugs on gametocyte clearance and sex ratio in African
children. In these children, artesunate-mefloquine cleared
gametocytamia significantly more rapidly than meflo-
quine alone [28-30] and may prevent transmission of the
infection. Although this impact may not be readily obvi-
ous in areas of intense transmission, in areas of low trans-
mission, this may have significant impact on malaria
incidence [28,31]. Compared to relatively non-immune
individuals living in areas of lesser intensity of transmis-
sion in Thailand, gametocyte clearance in the cohort of
children treated with artesunate-mefloquine was rela-
tively shorter (10 days versus five days). This, in addition
to other possibilities, raises a question: does immunity
increase drug-assisted gametocyte clearance? This is likely
since in endemic population immunity enhances the
clearance of asexual parasites [32].
Monocytes and leukocytes phagocytose early and late
stages of gametocytes, respectively [33,34]. It is unclear
how non-gametocytocidal anti-malarials interact with
this mechanism to produce clearance of gametocytes. Per-
Table 3: Clearance of gametocyte following treatment of P. falciparum infections in children with mefloquine or artesunate-
mefloquine
Drug treatment
Time to clearance of gametocyte (days) Artesunate-mefloquine Mefloquine P. value
1 31 29 0.017
2 37
3 43
4 41
5 2
6 13
7
8 1 10 0.026*
11 1
14 1
>14 7
GCT
Mean ± sem 1.8 ± 0.22 5.6 ± 0.95 0.001
Range 1-8 1-35
*Fisher exact testMalaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
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haps artemisinin drugs enhance the clearance of late
gametocytes while being at the same time directly game-
tocytocidal to early gametocytes.
Gametocyte sex ratio may be influenced by a number of
factors including anaemia, the number of and the compe-
tition between different parasite genotypes and other bio-
logical variables such as parasite density and transmission
rates [7-9,12,13]. Overall, sex ratio at presentation in the
cohort of children was male-biased in contrast to previous
findings from this endemic area [11] suggesting that, sex
ratios in natural population although female-biased may
be variable [7,35]. In order to examine the effects of anti-
malarials on the sex ratio allocation strategies of P. falci-
parum, an evaluation of the sex ratio of first-appearing
gametocytes was made. The assumption was that the sex
ratio of first-appearing gametocytes as opposed to sex
ratio of all gametocyte present in circulation would be a
more sensitive indicator of the effects of chemotherapy.
Based on this assumption, the finding was that, overall,
the sex ratio of first appearing gametocytes was male-
biased except on the third day after treatment began in the
artesunate-mefloquine group, when it became signifi-
cantly female-biased. Since the gametocytes emerging
immediately following treatment were already allocated
to sex several days before treatment began, the female-
biased sex ratio observed with artesunate-mefloquine
would suggest that the drug has no effect on sex allocation
strategy of the parasite. Therefore, it is likely that the
observed female-biased sex ratio is due to preferential
release, into peripheral blood, of female gametocytes or a
selective killing effect on male gametocytes. The effect (s)
on emergence, however, was short-lived, and may have
been blunted by the relatively long half-life of mefloquine
of 16-33 days [36] exerting a more profound effect than
artesunate with a very short half-life. Thus, it is possible
that partner drugs in artemisinin-based combinations
may modify their female-biased sex ratio producing
effects as previously demonstrated for artesunate-amodi-
aquine combination [37]. Another possible reason is that
male gametocytes are longer-lived [38,39]. Studies are
now needed to assess the effects of artemisinin mono-
therapy on the sex ratio of first appearing gametocytes and
the temporal changes in the sex ratio of cohorts of first-
appearing gametocytes in falciparum infections.
Temporal changes in mean gametocyte sex ratio in children treated with mefloquine (MQ) or artesunate-mefloquine (AMQ) Figure 4
Temporal changes in mean gametocyte sex ratio in children treated with mefloquine (MQ) or artesunate-
mefloquine (AMQ).
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Plasmodium species may increase their chances of trans-
mission by investing in gametocyte production or in sex
allocation [9]. It would appear from the results of the
present study that after treatment with mefloquine or
artesunate-mefloquine, P. falciparum increased its invest-
ment significantly in gametocyte production but not in
sex allocation suggesting that induction of gametocy-
togenesis and sex determination may have different mech-
anisms.
In addition to the density of peripheral gametocytes [40]
and the duration of carriage, the sex ratio of the gameto-
cyte may play a role in transmission success since the ratio
may impact on mosquito infectivity [17]. Following
AUCgm was approximately three-fold higher in meflo-
quine than in artesunate-mefloquine treated children.
Assuming sex ratio is related to mosquito infectivity, the
higher value, coupled with a higher AUCgm treatment for
mefloquine should presumably put patients treated with
mefloquine at a higher risk for mosquito infectivity and
transmissibility if the gametocytes were viable.
There are potential implications of the findings of the
present study: primaquine is gametocytocidal and can
shorten gametocyte clearance time [29,41] but its inclu-
sion as part of artemisinin-based combination therapy is
fraught with the danger of inducing haemolysis in a pop-
ulation where the child prevalence of glucose phosphate
dehydrogenase (G6PD) deficiency may be close to 20% or
where anti-malarial (dapsone)-induced haemolysis may
be a potential public health problem (Premji et al.,
unpublished observation) or where malaria-associated
anaemia is a public health problem [42] and is associated
with an increased risk of gametocyte carriage and sex ratio
changes that may influence transmission [43]. There is
need to find combination drugs that are safe and can rap-
idly clear gametocytaemia in children (and adults) with
falciparum malaria living in areas of intense transmission
in Africa. Tafenoquine in combination with artemisinin-
based combination therapy may be able to play this role.
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(AMQ).
MQ AMQ MQ AMQ MQ AMQ
0.0
0.5
1.0
Day 1 Day 2 Day 3
S
e
x
r
a
t
i
o
o
f
f
i
r
s
t
a
p
p
e
a
r
i
n
g
g
a
m
e
t
o
c
y
t
e
sMalaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
Page 12 of 13
(page number not for citation purposes)
Authors' contributions
AS led the design, conduct, data analysis and manuscript
preparation. OON and TMO were involved with conduct
and data analysis. GOG and CTH were involved in design,
conduct, and preparation of the manuscript. EOA was
involved with data analysis and manuscript preparation.
All authors read and approved the manuscript.
Acknowledgements
We thank the patients and their parents for participating in the study. We 
are grateful to our colleagues and assistants who participated in the running 
of the clinic.
References
1. Beier JC: Malaria parasite development in mosquitoes.  Annu
Rev Entomol 1998, 43:519-543.
2. Hogh B, Gamage-Mendis A, Butcher GA, Thompson R, Begtrup K,
Mendis C, Enosse SM, Dgedge M, Barreto J, Eling W, Sinden RE: The
differing impact of chloroquine and pyrimethamine/sulf-
adoxine upon the infectivity of malaria species to its vector.
Am J Trop Med Hyg 1998, 58:176-182.
3. Ross A, Killeen G, Smith T: Relationships between host infectiv-
ity to mosquitoes and asexual parasite density in Plasmodium
falciparum .  Am J Trop Med Hyg 2006, 75(suppl 2):32-37.
4. Smalley ME, Sinden RE: Plasmodium falciparum gametocytes:
their longevity and infectivity.  Parasitology 1977, 74:1-8.
5. Eichner M, Diebner HH, Molineaux L, Collins WE, Jeffery GM, Dietz
K: Genesis, sequestration and survival of Plasmodium falci-
parum  gametocytes: parameter estimates from fitting a
model to malariotherapy data.  Trans R Soc Trop Med Hyg 2001,
95:297-501.
6. Sowunmi A, Fateye BA: Changes in Plasmodium falciparum
gametocytaemia in children with chloroquine-sensitive asex-
ual infections.  Parasite 2003, 10:363-369.
7. Paul RE, Coulson TN, Raibaud A, Brey PT: Sex determination in
malaria parasites.  Science 2000, 287:128-131.
8. Robert V, Sokhna CS, Rogier C, Ariey F, Trape J-F: Sex ratio of Plas-
modium falciparum gametocytes in inhabitants of Dielmo,
Senegal.  Parasitology 2003, 127:1-8.
9. Reece SE, Duncan AB, West SA, Read AF: Host cell preference
and variable transmission strategies in malaria parasites.
Proc R Soc B 2005, 272:511-517.
10. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT: Plasmodium fal-
ciparum gametocyte sex ratios in children with acute uncom-
plicated symptomatic infection treated with amodiaquine.
Malar J 2008, 7:169.
11. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT: Plasmodium fal-
ciparum  gametocyte sex ratios in symptomatic children
treated with antimalarial drugs.  Acta Trop 2009, 109:108-117.
12. Reece SE, Drew DR, Gardner A: Sex ratio adjustment and kin
discrimination in malaria parasites.  Nature 2008, 453:609-615.
13. West SA, Smith TG, Nee S, Read AF: Fertility insurance and the
sex ratios of malaria and related hemosporin blood para-
sites.  J Parasitol 2002, 88:258-263.
14. Salako LA, Ajayi FO, Sowunmi A, Walker O: Malaria in Nigeria: a
revisit.  Ann Trop Med Parasitol 1990, 84:435-445.
15. World Health Organization: Severe falciparum malaria.  Trans R
Soc Trop Med Hyg 2000, 94(Suppl 1):1-90.
16. Carter R, Graves PM: Gametocytes. Malaria: Principles and Practice of
Malariology  Volume I. Edited by: Wernsdorfer WH, McGregor I.
Churchill Livingstone, Edingburgh; 1988:253-303. 
17. Robert V, Read AF, Essong J, Tchuinkam T, Mulder B, Verhave JP,
Carnevale P: Effects of gametocyte sex ratio on infectivity of
Plasmodium falciparum to Anopheles gambiae.  Trans R Soc Trop
Med Hyg 1996, 90:621-624.
18. Pickering J, Read AF, Guerrero S, West SA: Sex ratio and viru-
lence in two species of lizard malaria parasites.  Evol Ecol Res
2000, 2:171-184.
19. Anonymous: Epi Info Version 6: A Word Processing Data Base and Statis-
tics Program for Public Health on IBM-compatible Microcomputers Cent-
ers for Disease Control and Prevention, Atlanta, GA; 1994. 
20. Anonymous: SPSS for Windows Release 10.01(Standard Version) SPSS
Inc., Chicago, IL, USA; 1999. 
21. von Seidlein L, Drakeley C, Greenwood B, Walraven G, Targett G:
Risk factors for gametocyte carriage in Gambian children.
Am J Trop Med Hyg 2001, 65:523-526.
22. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M,
Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG,
Krishna S, Lell B, Loolpapit M, Matsiegui P-B, Missinou MA, Mwanza J,
Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WRJ:
Amodiaquine-artesunate versus amodiaquine for uncompli-
cated Plasmodium falciparum malaria in African children: a
randomised, multicentre trial.  Lancet 2002, 359:1365-1372.
23. Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Happi TC: Risk
factors for gametocyte carriage in uncomplicated falci-
parum malaria in children.  Parasitology 2004, 129:255-262.
24. Bousema JT, Schneider P, Gougna LC, Drakeley CJ, Tostmann A,
Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, Sauerwein
RW: Moderate effect of artemisinin based combination ther-
apy on transmission of.  Plasmodium falciparum. J Inf Dis 2006,
193:1151-1159.
25. Shekalaghe SA, Bousema JT, Kunel KK, Lushino P, Masokoto A, Wol-
ters LR, Mwakalinga S, Mosha FW, Sauerwein RW, Drakeley CJ: Sub-
microscopic Plasmodium falciparum gametocyte carriage is
common in an area of low and seasonal transmission in Tan-
zania.  Trop Med Int Health 2007, 12:547-553.
26. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'
Neil M, Milhous W, Wirth DF, Oduola AMJ: Selection of Plasmo-
dium falciparum multi-drug resistance gene 1 alleles in asex-
ual stages and gametocytes by artemether-lumefantrine in
Nigerian children with uncomplicated falciparum malaria.
Antimicrob Agents 2009, 53:888-895.
27. Piyaphanee W, Krudsood S, Tangpukdee N, Thanachartwet W, Sila-
chamroon U, Phophak N, Duangdee C, Haoharn O, Faithong S, Wilai-
ratana P, Leowattana W, Looaresuwan S: Emergence and
clearance of gametocytes in uncomplicated Plasmodium fal-
ciparum malaria.  Am J Trop Med Hyg 2006, 74:432-435.
28. Price N, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chong-
suphajasiddhi T, White NJ: Effects of artemisinin derivatives on
malaria transmissibility.  Lancet 1996, 347:1654-1658.
29. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim
K, Chanthapakajee K, Kaewkaukul N, Thamlikitkul V: The efficacy
of combined mefloquine-qrtesunate versus mefloquine-pri-
maquine on subsequent development of Plasmodium falci-
parum gametocytemia.  Am J Trop Med Hyg 2003, 68:620-623.
30. Tangpukdee N, Krudsood S, Srivilairit S, Phophak N, Chonsawat P,
Yanpanich W, Kano S, Wilairatana P: Gametocyte clearance in
uncomplicated and severe Plasmodium falciparum malaria
after artesunate-mefloquine treatment in Thailand.  Korean J
Parasitol 2008, 46:65-70.
31. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman
A, McGready R, ter Kuile F, Looaresuwan S, White NJ: Effects of
artesunate-mefloquine combination on incidence of Plasmo-
dium falciparum malaria and mefloquine resistance in west-
ern Thailand.  Lancet 2000, 356:297-302.
32. Djimde A, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte
Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M,
Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatowski D, Plowe CV:
Clearance of drug-resistant parasites as a model for protec-
tive immunity in Plasmodium falciparum malaria.  Am J Trop
Med Hyg 2003, 69:558-563.
33. Smith TG, Serghides L, Patel SN, Febbraio M, Silverstein RL, Kain KC:
CD36-Mediated nonopsonic phagocytosis of erythrocytes
infected with sage I and IIa gametocytes of Plasmodium falci-
parum .  Inf Immun 2003, 71:393-400.
34. Sinden RE, Smalley ME: Gametocytes of Plasmodium falciparum:
phagocytosis by leucocytes in vivo and in vitro.  Trans R Soc Trop
Med Hyg 1976, 70:344-345.
35. Schall JJ: The sex ratio of Plasmodium gametocytes.  Parasitology
1989, 98:343-350.
36. Desjardins RE, Pamplin CL, von Bredow J, Barr KG, Canfield CJ:
Kinetics of a new antimalarial, mefloquine.  Clin Pharmacol
Therap 1979, 26:372-379.
37. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT, Adedeji AA,
Fehintola FA: Activities of amodiaquine, artesunate, and
artesunate-amodiaquine against asexual- and sexual-stagePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2009, 8:297 http://www.malariajournal.com/content/8/1/297
Page 13 of 13
(page number not for citation purposes)
parasites in falciparum malaria in children.  Antimicrob Agents
Chemother 2007, 51:1694-1699.
38. Reece SE, Duncan AB, West SA, Read AF: Sex ratios in the rodent
malaria parasite, Plasmodium chabaudi .  Parasitology 2003,
127:419-425.
39. Sowunmi A, Fateye BA: Plasmodium falciparum gametocytaemia
in Nigerian children: before, during and after treatment with
antimalarial drugs.  Trop Med Int Health 2003, 8:783-792.
40. Tchuinkam T, Mulder B, Dechering K, Stoffels H, Verhave JP, Cot M,
Carnevale P, Meuwissen JH, Robert V: Experimental infections of
Anopheles gambiae with Plasmodium falciparum of naturally
infected gametocyte carriers in Cameroon: factors influenc-
ing the infectivity to mosquitoes.  Trop Med Parasitol 1993,
44:271-276.
41. Luxemburger C, Thwai K, White NJ, Webster HK, Kyle DE, Maelan-
kirri L, Chongsuphajaisiddhi T, Nosten F: The epidemiology of
malaria in a Karen population on the western border of Thai-
land.  Trans R Soc Trop Med Hyg 1996, 90:105-111.
42. Crawley J: Reducing the burden of anemia in infants and
young children in malaria-endemic countries of Africa: from
evidence to action.  Am J Trop Med Hyg 2004, 71:25-34.
43. Sowunmi A, Balogun ST, Gbotosho GO, Happi CT: Influence of
anaemia on Plasmodium falciparum gametocyte sex ratios in
acutely symptomatic children.  Open Trop Med J 2008, 1:13-20.